Rezolute reports 13 responders in preliminary Phase 3 tumor study
Twelve participants stopped intravenous glucose, while final statistics are due in December and a US$100M offering is expected to close Nov. 16.
Adrian Kessler
A Phase 3 study crossed its preliminary response threshold for tumor-related hypoglycemia after Rezolute, Inc. NASDAQRZLT reported on Friday that 13 of 16 participants responded to ersodetug. Twelve participants stopped intravenous glucose entirely, but the completed study's statistical analysis is due by mid-December 2026.
The Nov. 5 evaluation measured reductions in glucose infusion requirements in the single-arm, open-label upLIFT trial. Three participants remained in the pivotal treatment period, including two who had not met the response criterion.
Rezolute is a small drug developer based in Redwood City, Calif., focused on rare metabolic diseases involving persistent low blood sugar.
Shares closed at US$3.87 on Nasdaq on Nov. 12, according to Google Finance's 4:00 p.m. EST timestamp for NASDAQRZLT. That quotation precedes Friday's announcements and does not measure the market's response.
Thirteen Participants Met The Response Threshold
The primary endpoint is the proportion achieving at least a 50 per cent reduction from baseline in glucose infusion rate, a measure of dependence on intravenous glucose. Statistical success requires the lower bound of the response rate's 95 per cent confidence interval to exceed 30 per cent.
Rezolute says nine responders would meet that threshold with the enrolled population. The completed statistical analysis is expected by mid-December.
Participants receive ersodetug at nine milligrams per kilogram weekly for eight weeks alongside standard care. The comparison is with their own baseline infusion requirements, without a placebo or active-treatment control.
The enrolled group includes 12 participants with malignant insulin-secreting tumors and four with non-islet cell tumors. Both can cause dangerously low blood sugar through excessive activation of the insulin receptor, which ersodetug targets.
Rezolute reported no drug-related safety findings to date; one participant who discontinued treatment for home hospice died from cancer progression and was counted as a nonresponder.
"[T]hese results substantially mirror the powerful outcomes that we have observed over the last few years in our expanded access program," Rezolute founder and chief executive Nevan Charles Elam said in the release.
An Offering Adds A Nearer Financing Date
Rezolute separately priced an underwritten offering on Nov. 13 expected to raise approximately US$100 million before fees. Closing is expected on or about Nov. 16, subject to customary conditions.
The offering includes 22,040,976 common shares at US$3.87 each, matching the quoted prior close. It also includes pre-funded warrants for another 3.8 million shares, priced at US$3.869 each with a US$0.001 exercise price.
Including warrant shares, the proposed issuance equals about 27 per cent of the common shares outstanding on Nov. 2, calculated from the latest quarterly filing. Proceeds are intended for commercialization preparation, working capital and general corporate purposes.
Rezolute's Nov. 5 financial update reported US$90 million in cash, cash equivalents and marketable securities at Sept. 30.
The same update said the separate congenital hyperinsulinism trial missed its primary endpoint against placebo. According to Rezolute, the FDA subsequently recommended a biologics application for review after a pre-submission meeting, following examination of additional data.
Friday's upLIFT description does not detail FDA agreement on the tumor trial's statistical plan. Ersodetug remains investigational, and the company expects FDA discussions in the first quarter of 2027.
Read more: Kyverna Therapeutics completes miv-cel BLA for stiff person syndrome
Among other listed drug developers, Mirum Pharmaceuticals, Inc. NASDAQMIRM closed at US$93.33 on Nasdaq on Nov. 12, according to Google Finance's 4:00 p.m. EST timestamp. The broader State Street SPDR S&P Biotech ETF NYSEARCAXBI was US$151.20 at the page's Nov. 12, 8:00 p.m. EST timestamp.
Read more: Mirum Pharmaceuticals meets Phase 3 hepatitis delta trial endpoint
The next clinical milestone is the completed upLIFT topline report by mid-December 2026, which will provide the final primary-endpoint analysis ahead of the planned FDA discussions.
